We are live on ! Find out more
CPRX

Catalyst Pharmaceutical
CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

Back to rankings

101 hedge funds and large institutions have $236M invested in Catalyst Pharmaceutical in 2019 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 38 increasing their positions, 19 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

107% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 14

100% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 19

15% more funds holding

Funds holding: 88 → 101 (+13)

0% less ownership

Funds ownership: 59.85% → 59.85% (-0%)

25% less capital invested

Capital invested by funds: $314M → $236M (-$77.4M)

43% less call options, than puts

Call options by funds: $981K | Put options by funds: $1.71M

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
101
Holders Change
+13
Holders Change %
+14.77%
% of All Funds
2.19%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
29
Increased
38
Reduced
19
Closed
14
Calls
$981K
Puts
$1.71M
Net Calls
-$733K
Net Calls Change
-$228K

Top Buyers

1
AC
Armistice Capital
New York
+$15M
2
BlackRock
BlackRock
New York
+$4.71M
3
AI
Atom Investors
Texas
+$3.15M
4
N
Nuveen
North Carolina
+$1.7M
5
MP
Mangrove Partners
Connecticut
+$1.64M

Top Sellers

1
BC
Broadfin Capital
New York
-$13.4M
2
OM
Opaleye Management
Massachusetts
-$9.31M
3
KCM
Kennedy Capital Management
Missouri
-$5.1M
4
HRCM
Hawk Ridge Capital Management
California
-$3.34M
5
EI
EAM Investors
California
-$2.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
AG
101
Aperio Group
California
$1K +$829 +192 New
OM
102
Opaleye Management
Massachusetts
– -$9.31M -1,825,000 Closed
KCM
103
Kennedy Capital Management
Missouri
– -$5.1M -999,787 Closed
HRCM
104
Hawk Ridge Capital Management
California
– -$3.34M -654,859 Closed
EI
105
EAM Investors
California
– -$2.54M -498,844 Closed
EGI
106
EAM Global Investors
California
– -$1.41M -276,228 Closed
AA
107
ALPS Advisors
Colorado
– -$1.27M -248,154 Closed
PVI
108
Pura Vida Investments
New York
– -$1.01M -197,594 Closed
PPA
109
Parametric Portfolio Associates
Washington
– -$952K -186,708 Closed
VF
110
Virtu Financial
New York
– -$574K -112,568 Closed
SEI Investments
111
SEI Investments
Pennsylvania
– -$572K -112,169 Closed
II
112
Ibex Investors
Colorado
– -$215K -42,098 Closed
FIA
113
FNY Investment Advisers
New York
– -$104K -20,500 Closed
WG
114
Winton Group
United Kingdom
– -$64K -12,454 Closed
RFC
115
Regions Financial Corp
Alabama
– -$5K -1,000 Closed
1 2 3 4
5

CPRX Hedge Fund Activity: Q2 2019 in Review

101 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2019, worth a combined $236M — down 25% from $314M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new CPRX positions and 14 closed out — a net gain of 15 holders — while 38 added to existing stakes and 19 trimmed.

The largest buyer was Armistice Capital, adding an estimated $15M. The largest seller was Broadfin Capital, cutting an estimated $13.4M.

  • 101 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2019, up from 88 in Q1 2019.
  • Funds reported $236M of Catalyst Pharmaceutical stock for Q2 2019, down 25% quarter-over-quarter.
  • 29 funds opened new Catalyst Pharmaceutical positions in Q2 2019 and 14 closed out, a net change of +15 holders.
  • The largest Catalyst Pharmaceutical buyer in Q2 2019 was Armistice Capital, an estimated $15M added.
  • The largest Catalyst Pharmaceutical seller in Q2 2019 was Broadfin Capital, an estimated $13.4M sold.

Based on aggregated 13F filings for Q2 2019.